NeuroSense Therapeutics Regains Nasdaq Compliance
Ticker: NRSNW · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1875091
Sentiment: bullish
Topics: compliance, listing-requirements, press-release
Related Tickers: NSRS
TL;DR
NeuroSense Therapeutics back in Nasdaq's good graces, no delisting fears for now.
AI Summary
On January 6, 2025, NeuroSense Therapeutics Ltd. announced it has regained compliance with Nasdaq's minimum equity requirement. The company is now in compliance with all Nasdaq listing rules, avoiding potential delisting.
Why It Matters
Regaining compliance with Nasdaq's minimum equity requirement is crucial for NeuroSense Therapeutics to maintain its listing on the exchange, ensuring continued access to capital markets and investor confidence.
Risk Assessment
Risk Level: medium — While regaining compliance is positive, the company's financial health and ability to sustain this compliance in the future remain key concerns.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — The company filing the report and announcing compliance.
- Nasdaq (company) — The stock exchange where NeuroSense Therapeutics is listed and whose requirements were met.
- January 6, 2025 (date) — The date of the press release announcing compliance.
FAQ
What specific Nasdaq listing requirement did NeuroSense Therapeutics regain compliance with?
NeuroSense Therapeutics regained compliance with Nasdaq's minimum equity requirement.
What is the date of the announcement regarding Nasdaq compliance?
The announcement was made on January 6, 2025.
What is the company's ticker symbol?
The filing does not explicitly state the ticker symbol, but the company name is NeuroSense Therapeutics Ltd.
What is the principal executive office address of NeuroSense Therapeutics?
The principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Does NeuroSense Therapeutics file annual reports under Form 20-F or Form 40-F?
NeuroSense Therapeutics indicated that it files annual reports under Form 20-F.
Filing Stats: 254 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-01-06 10:40:14
Filing Documents
- ea0226872-6k_neuro.htm (6-K) — 10KB
- ea022687201ex99-1_neuro.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 28KB
- 0001213900-25-000994.txt ( ) — 65KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: January 6, 2025 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2